Galectin Therapeutics reported $71.74M in Debt for its fiscal quarter ending in December of 2023.





Debt Change Date
AbbVie USD 70.82B 2.04B Jun/2026
Bristol-Myers Squibb USD 42.88B 2.18B Sep/2026
Galectin Therapeutics USD 71.74M 10.6M Dec/2023
Gilead Sciences USD 26.25B 4.07B Jun/2026
Immunic USD 0 0 Jun/2024
Incyte USD 38.27M 1.16M Jun/2026
Merck USD 53.91B 4.79B Jun/2026